Cardiovascular Diseases among Patients with Cancer and Patients living with HIV

项目概要/摘要：Tomas Neilan MD MPH是心脏病科的临床活跃心脏病专家， 马萨诸塞州总医院的心脏病学和心血管成像， 医学在哈佛医学院。在过去的10年里，尼兰博士的研究集中在应用 将先进的成像技术应用于两个互补的领域，即与癌症治疗相关的心血管毒性 和心力衰竭的风险。尼兰博士丰富的指导经验，出版物和 资金记录，连同他目前和计划的研究支持，证明了他的承诺， 对POR充满热情，并为实现K24奖的目标和目的奠定了良好的基础。 K24奖的具体目标是：1）使Neilan博士能够贡献25%的 他的时间来指导初级临床研究人员的基础上已经NIH资助的项目; 2）指导初级 来自T-32项目的临床研究人员以及心脏病学的住院医师、研究员和初级教员 和放射学的目标是发展他们成为临床研究人员谁可以成功地竞争同行 审查赠款;和3）为了使Neilan博士能够巩固一个结合创新翻译， 心血管成像的临床和结果研究，并提供了一个理想的环境， 临床研究的未来领导者。Neilan博士目前的领导角色与该提案非常一致。他是 心脏MR CT PET项目（一项心血管成像临床研究项目）的联合主任 在心脏科和放射科的支持下，MGH副主任 T32心血管成像培训补助金，以及该部门的肿瘤学计划主任 心脏病学除了他的角色之外，Neilan博士还毫无保留地致力于 心脏病学和放射学提供了一个基础，是理想的成功指导初级临床 研究人员和实现奖励的目的。这项补助金的具体研究目标源于一个 在过去几年中完成的大量工作，都是基于正在进行的NIH资助的 项目，但目标4除外，这是一项特别由本补助金资助的新研究： 1)STOP-CA -在一项随机多中心临床试验中检验他汀类药物对左室舒张功能降低的影响 基于蒽环类药物化疗后的心室射血分数，2）REPRIEVE-MR测试， 随机多中心临床试验是否他汀类药物减少心肌纤维化，心肌脂肪变性和 保护艾滋病毒感染者的心脏功能，3）STOP-CA纤维化-我们应用新型MRI- 基于成像技术，以深入了解心肌纤维化在发展中的作用， 蒽环类药物诱导的心脏毒性，并测试他汀类药物对蒽环类药物后心肌纤维化的影响， 和4）扩大我们的国际登记，以改善我们对预测因子，介绍， 免疫检查点抑制剂（ICI）治疗后出现心肌炎的患者的治疗和结局。

Project Summary/Abstract: Tomas Neilan MD MPH is a clinically-active cardiologist in the Division of Cardiology and Cardiovascular Imaging at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Over the last 10 years, Dr. Neilan’s research has focused on applying advanced imaging to two complementary areas, the cardiovascular toxicities associated with cancer therapies and heart failure among persons with HIV. Dr. Neilan’s extensive mentoring experience, publication and funding record, together with his current and planned research support, demonstrate his commitment and passion for POR and provide an excellent foundation to accomplish the goals and objectives of the K24 Award. The specific aims addressing the purpose of the K24 Award are: 1) To enable Dr. Neilan to dedicate 25% of his time to mentor junior clinical investigators based on already NIH funded projects; 2) To mentor junior clinical investigators from the T-32 program and the pool of residents, fellows, and junior faculty in Cardiology and Radiology with the goal to develop them into clinical researchers who can successfully compete for peer reviewed grants; and 3) To enable Dr. Neilan to consolidate a POR that combines innovative translational, clinical, and outcomes research in cardiovascular imaging and that provides an ideal environment to develop future leaders in clinical research. Dr. Neilan’s current leadership roles align well with this proposal. He is the Co-Director of the Cardiac MR CT PET Program, a clinical research program in cardiovascular imaging supported by the Division of Cardiology and the Department of Radiology, the Associate Director of the MGH T32 training grant in cardiovascular imaging, and the Director of the Cardio-Oncology Program in the Division of Cardiology. In addition to his roles, Dr. Neilan also has an unreserved commitment from the leadership of both Cardiology and Radiology providing a foundation that is ideal to successfully mentor junior clinical investigators and fulfill the purpose of the Award. The specific research aims of this grant stem from a significant body of work accomplished over the past few years and are all based on on-going NIH funded projects, except Aim 4 which is new research specifically supported by this grant: 1) STOP-CA – Testing in a randomized multicenter clinical trial the effect of statins on the reduction in left ventricular ejection fraction after anthracycline-based chemotherapy, 2) REPRIEVE-MR – Testing in a randomized multicenter clinical trial whether statins reduce myocardial fibrosis, myocardial steatosis and preserve cardiac function among persons living with HIV, 3) STOP-CA Fibrosis – where we apply novel MRI- based imaging techniques to provide insight into the role of myocardial fibrosis in the development of anthracycline-induced cardiotoxicity, and test the effect of statins on myocardial fibrosis after anthracyclines, and 4) Expanding our international registry to improve our limited understanding of the predictors, presentation, treatments and outcomes of patients presenting with myocarditis after immune checkpoint inhibitors (ICI’s).